Home » Stocks » PCRX

Pacira Biosciences, Inc. (PCRX)

Stock Price: $60.61 USD -1.42 (-2.29%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $60.80 +0.19 (0.31%) Dec 4, 5:44 PM

PCRX Stock Price Chart

Key Info

Market Cap 2.70B
Revenue (ttm) 421.10M
Net Income (ttm) 126.12M
Shares Out 42.93M
EPS (ttm) 2.93
PE Ratio 20.68
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $60.61
Previous Close $62.03
Change ($) -1.42
Change (%) -2.29%
Day's Open 62.15
Day's Range 60.13 - 62.18
Day's Volume 313,066
52-Week Range 28.40 - 66.26

PCRX Stock News

GlobeNewsWire - 1 week ago

PARSIPPANY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Confe...

Zacks Investment Research - 2 weeks ago

The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in ...

GlobeNewsWire - 2 weeks ago

--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachia...

GlobeNewsWire - 3 weeks ago

-- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 -- -- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 --

GlobeNewsWire - 3 weeks ago

PARSIPPANY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at ...

Zacks Investment Research - 1 month ago

Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.

Seeking Alpha - 1 month ago

Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 month ago

Pacira (PCRX) delivered earnings and revenue surprises of 3.03% and 1.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 month ago

-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET --

Zacks Investment Research - 1 month ago

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 month ago

--The Pacira Innovation and Training Center of Tampa will provide clinicians with a flexible environment for hands-on learning-- PARSIPPANY, N.J., and TAMPA, Fla., Oct. 21, 2020 (GLOBE NEWSWIR...

Zacks Investment Research - 1 month ago

Pacira BioSciences (PCRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 1 month ago

PARSIPPANY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. m...

Zacks Investment Research - 1 month ago

Is (PCRX) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 1 month ago

-- EXPAREL average daily sales at 110% of the prior year for the third quarter and 110% of the prior year for the month of September -- PARSIPPANY, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Paci...

Zacks Investment Research - 2 months ago

The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

GlobeNewsWire - 2 months ago

-- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery -- -- European Commission decision on the Marketing Authorization Appli...

GlobeNewsWire - 2 months ago

ALPHARETTA, Ga. and PARSIPPANY, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- IPG, the industry-leading provider of surgical cost management solutions, and Pacira BioSciences, Inc. (NADSAQ: PCRX)...

GlobeNewsWire - 2 months ago

PARSIPPANY, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 H.C. Wainwright 22nd Annual Global Investment ...

GlobeNewsWire - 2 months ago

-- EXPAREL average daily sales at 111% of the prior year for the month of August 2020 -- PARSIPPANY, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a lead...

Zacks Investment Research - 2 months ago

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 3 months ago

Pacira BioSciences's (PCRX) CEO David Stack on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.

Zacks Investment Research - 3 months ago

Pacira (PCRX) delivered earnings and revenue surprises of -25.00% and -0.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Paci...

GlobeNewsWire - 3 months ago

PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference a...

GlobeNewsWire - 3 months ago

– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery –

GlobeNewsWire - 4 months ago

sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over

GlobeNewsWire - 4 months ago

PARSIPPANY, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S...

Zacks Investment Research - 4 months ago

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GlobeNewsWire - 4 months ago

Pacira to Pay $3.5 Million to Settle Various Claims with No Admission of Wrongdoing Pacira to Pay $3.5 Million to Settle Various Claims with No Admission of Wrongdoing

Zacks Investment Research - 4 months ago

Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research - 4 months ago

Top Ranked Momentum Stocks to Buy for July 21st

Other stocks mentioned: EBS, TSM, USNA
Zacks Investment Research - 4 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: AMRC, CSIQ, EBS, NLS
Zacks Investment Research - 4 months ago

Top Ranked Momentum Stocks to Buy for July 10th

Other stocks mentioned: BSIG, NLS, UMRX
GlobeNewsWire - 4 months ago

PARSIPPANY, N.J., July 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior not...

Zacks Investment Research - 4 months ago

Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic.

Zacks Investment Research - 4 months ago

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Other stocks mentioned: ALPN, ATNM, TBIO
GlobeNewsWire - 4 months ago

PARSIPPANY, N.J., July 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $300.0 million a...

GlobeNewsWire - 4 months ago

-- EXPAREL average daily sales return to year-over-year growth for month of June 2020 -- -- EXPAREL average daily sales return to year-over-year growth for month of June 2020 --

Zacks Investment Research - 5 months ago

As of late, it has definitely been a great time to be an investor of Pacira BioSciences

Zacks Investment Research - 5 months ago

Pacira (PCRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

GlobeNewsWire - 5 months ago

-- Orthopedic co-promotion agreement to conclude in January 2021 -- -- Significantly improves Pacira economics related to EXPAREL --

The Motley Fool - 5 months ago

Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.

GlobeNewsWire - 5 months ago

PARSIPPANY, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 BMO Prescriptions for Success Healthcare Confer...

Zacks Investment Research - 5 months ago

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 6 months ago

PCRX vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
Seeking Alpha - 6 months ago

Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.

Zacks Investment Research - 6 months ago

Pacira (PCRX) delivered earnings and revenue surprises of 65.62% and 4.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

About PCRX

Pacira BioSciences provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold tempera... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 3, 2011
CEO
David M. Stack
Employees
606
Stock Exchange
NASDAQ
Ticker Symbol
PCRX
Full Company Profile

Financial Performance

In 2019, PCRX's revenue was $421.03 million, an increase of 24.83% compared to the previous year's $337.28 million. Losses were -$11.02 million, 2,238.9% more than in 2018.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is 66.38, which is an increase of 9.52% from the latest price.

Price Target
$66.38
(9.52% upside)
Analyst Consensus: Buy